111 related articles for article (PubMed ID: 15651719)
1. Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan.
Morishita Y; Fujii M; Kasakura Y; Takayama T
J Int Med Res; 2005; 33(1):84-9. PubMed ID: 15651719
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
[TBL] [Abstract][Full Text] [Related]
3. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.
Uchino J; Takayama K; Harada A; Sone T; Harada T; Curiel DT; Kuroki M; Nakanishi Y
Cancer Gene Ther; 2008 Feb; 15(2):94-100. PubMed ID: 18157147
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
7. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
8. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Miki T; Sawada M; Nonomura N; Kojima Y; Okuyama A; Maeda O; Saiki S; Kotake T
Eur Urol; 1997; 31(1):92-6. PubMed ID: 9032542
[TBL] [Abstract][Full Text] [Related]
11. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
12. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Oosterhoff D; Witlox MA; van Beusechem VW; Haisma HJ; Schaap GR; Bras J; Kruyt FA; Molenaar B; Boven E; Wuisman PI; Pinedo HM; Gerritsen WR
Mol Cancer Ther; 2003 Aug; 2(8):765-71. PubMed ID: 12939466
[TBL] [Abstract][Full Text] [Related]
13. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
14. Future directions for clinical research with CPT-11 (irinotecan).
von Hoff D
Eur J Cancer; 1996; 32A Suppl 3():S9-12. PubMed ID: 8943659
[TBL] [Abstract][Full Text] [Related]
15. Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice.
Yi BR; Kim SU; Choi KC
Oncotarget; 2014 Dec; 5(24):12835-48. PubMed ID: 25544747
[TBL] [Abstract][Full Text] [Related]
16. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Gutova M; Shackleford GM; Khankaldyyan V; Herrmann KA; Shi XH; Mittelholtz K; Abramyants Y; Blanchard MS; Kim SU; Annala AJ; Najbauer J; Synold TW; D'Apuzzo M; Barish ME; Moats RA; Aboody KS
Gene Ther; 2013 Feb; 20(2):143-50. PubMed ID: 22402322
[TBL] [Abstract][Full Text] [Related]
17. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
Huisman SA; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; IJzermans JN; Wiemer EA; Mathijssen RH; de Bruin RW
Br J Pharmacol; 2016 Mar; 173(5):804-14. PubMed ID: 26332723
[TBL] [Abstract][Full Text] [Related]
18. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
19. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
[TBL] [Abstract][Full Text] [Related]
20. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.
Kojima A; Hackett NR; Crystal RG
Cancer Res; 1998 Oct; 58(19):4368-74. PubMed ID: 9766666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
